European Approval For BioControl Medical’s Nerve Stimulation System For Treatment-Resistant Depression
Executive Summary
BioControl Medical’s FitNeS vagus nerve stimulation system now has a second approved European indication: treatment-resistant depression. This follows the implantable neuromodulation system’s first CE mark for drug-resistant epilepsy in 2010.
You may also be interested in...
Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
Boston Scientific and Cyberonics report disappointing data on vagus nerve stimulation to treat heart failure at the European Society of Cardiology conference in Barcelona. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market
Emerging technologies in peripheral nerve stimulation are expected to play a pivotal role in opening up new markets and driving growth in the neuromodulation device market in the years ahead. As a result, the pipeline is rich with products designed to address a growing number of patients with long-term pain and other chronic conditions, many of whom have no other treatment options.